Role and place of levofloxacin in the treatment of community-acquired pneumonia
| Autor: | D V Dmytriiev, O A Nazarchuk, Yu M Babina |
|---|---|
| Jazyk: | Russian<br />Ukrainian |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Perioperative Medicine, Vol 3, Iss 2 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2616-339X 2617-2925 |
| DOI: | 10.31636/prmd.v3i2.6 |
| Popis: | Lower respiratory tract infections are the third mortality cause in the world and the first mortality cause in low-income countries. Community-acquired pneumonia (CAP) is a dangerous infectious pathology, especially in children younger than 5 years, elderly people and patients with compromised immunity. Antibiotic therapy is a standard treatment method for CAP. But an increase in antibiotics use caused a development of resistance in bacteria and onset of adverse events in humans. A new class of fluorchinolones is widely used nowadays in clinical practice. They have good activity against Gram-negative bacteria, as early chinolones, as well as against Gram-positive bacteria, such as pneumococci and atypical bacteria. An increasing amount of penicillin-resistant streptococcal pneumonia leads to more intensive studies of the use of new chinolones. In this review the data of 750 mg levofloxacin is presented. It is used in short courses for the treatment of severe and moderate CAP. Taking into account the broad spectrum of activity of levofloxacin ad bactericidal activity of this antibiotic, it can be a potential alternative therapy for the treatment of children and adults with CAP, especially with a tendency of an increase in antibiotic resistance of pneumococcus. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|